NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
- Conditions
- Recurrent Childhood Medulloblastoma
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT00822458
- Locations
- πΊπΈ
UCSF-Mount Zion, San Francisco, California, United States
πΊπΈChildren's National Medical Center, Washington, District of Columbia, United States
πΊπΈLurie Children's Hospital-Chicago, Chicago, Illinois, United States
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
- Conditions
- Stage IV Renal Cell CancerRecurrent Renal Cell Cancer
- First Posted Date
- 2009-01-13
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00019539
- Locations
- πΊπΈ
Surgery Branch, Bethesda, Maryland, United States
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
- Conditions
- Adult Solid Neoplasm
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00813423
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈRutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals
- Conditions
- Diabetes Mellitus Type 1Diabetes Mellitus Type 2
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2019-11-29
- Target Recruit Count
- 76
- Registration Number
- NCT00813228
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3
- Conditions
- HealthyThyroid Disease
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2017-10-06
- Target Recruit Count
- 86
- Registration Number
- NCT00812149
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Human Papillomavirus Epidemiology in Nigeria
- Conditions
- Human Papillomavirus 18Human Papillomavirus 16Uterine Cervical NeoplasmsCervical Intraepithelial Neoplasia
- Interventions
- Device: OncoE6Device: EVA System
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1466
- Registration Number
- NCT00804466
- Locations
- π³π¬
Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
- Conditions
- Stage IVB Cervical CancerCervical Adenosquamous CarcinomaCervical AdenocarcinomaCervical Squamous Cell CarcinomaRecurrent Cervical Carcinoma
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 452
- Registration Number
- NCT00803062
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈUniversity of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
πΊπΈSaint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
- Conditions
- Papillomavirus VaccinesAdolescentHuman Immunodeficiency VirusHuman Papillomavirus- 6, 11, 16, 18
- Interventions
- Behavioral: Survey
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00798265
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Pure Erythroid Leukemia (M6b)Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- Other: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT00795002
- Locations
- πΊπΈ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
πΊπΈFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Case-Control Study of Inflammatory Breast Cancer in North Africa
- Conditions
- Diabetes
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 815
- Registration Number
- NCT00793390
- Locations
- πͺπ¬
National Cancer Institute-Cairo, Cairo, Egypt
πͺπ¬Gharbia Cancer Society, Gharbia, Egypt
πͺπ¬Tanta Cancer Center, Tanta, Egypt